Pacing in hypertrophic obstructive cardiomyopathy: A randomized crossover study
Why the study?
Does activated pacemaker therapy improve hemodynamics and symptoms in patients with hypertrophic obstructive cardiomyopathy refractory to drug treatment?
Population
83 patients with hypertrophic obstructive cardiomyopathy with symptoms refractory or intolerant to classical…
Comparison
Activated pacemaker therapy for 12 weeks. vs Non-activated pacemaker therapy for 12 weeks.
Design
RCT, Randomized cross-over, Double-blind
Follow-up
12 weeks per phase
Authors
Discussion
Loading...
Member takes
Implication
Supports dual-chamber pacing in drug-refractory HOCM; confirms LVOT gradient reduction and symptom relief in this RCT.
Structured PICO
Does activated pacemaker therapy improve hemodynamics and symptoms in patients with hypertrophic obstructive cardiomyopathy refractory to drug treatment?
P
Population
83 patients with hypertrophic obstructive cardiomyopathy (left ventricular outflow gradient at rest >30 mmHg) with symptoms refractory or intolerant to classical drug treatment, mean age 53 years.
I
Intervention
Activated pacemaker therapy (short atrioventricular delay dual chamber pacing) for 12 weeks.
C
Comparator
Non-activated pacemaker therapy for 12 weeks.
O
Outcome
Modification of echocardiography (pressure gradient), exercise tolerance, angina, dyspnoea, and quality of life at 12 weeks.surrogate
Dual chamber pacing significantly reduces left ventricular outflow tract gradient and improves symptoms in patients with drug-refractory hypertrophic obstructive cardiomyopathy.
Cite This Study
Kappenberger et al. (1997) studied this question.